TrialThe Lancet. Haematology2017

Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.

Lucia Masarova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.